AU2023221615A1 - Pharmaceutical formulation - Google Patents
Pharmaceutical formulation Download PDFInfo
- Publication number
- AU2023221615A1 AU2023221615A1 AU2023221615A AU2023221615A AU2023221615A1 AU 2023221615 A1 AU2023221615 A1 AU 2023221615A1 AU 2023221615 A AU2023221615 A AU 2023221615A AU 2023221615 A AU2023221615 A AU 2023221615A AU 2023221615 A1 AU2023221615 A1 AU 2023221615A1
- Authority
- AU
- Australia
- Prior art keywords
- amount
- amino
- pharmaceutically acceptable
- tablet
- pharmaceutical formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202211009181 | 2022-02-21 | ||
| IN202211009181 | 2022-02-21 | ||
| PCT/IB2023/051532 WO2023156979A1 (en) | 2022-02-21 | 2023-02-20 | Pharmaceutical formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2023221615A1 true AU2023221615A1 (en) | 2024-07-25 |
Family
ID=85476156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023221615A Pending AU2023221615A1 (en) | 2022-02-21 | 2023-02-20 | Pharmaceutical formulation |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250161223A1 (https=) |
| EP (1) | EP4482471A1 (https=) |
| JP (1) | JP2025508402A (https=) |
| KR (1) | KR20240150600A (https=) |
| CN (1) | CN118715005A (https=) |
| AU (1) | AU2023221615A1 (https=) |
| CA (1) | CA3251234A1 (https=) |
| IL (1) | IL314206A (https=) |
| MX (1) | MX2024009967A (https=) |
| TW (1) | TW202342040A (https=) |
| WO (1) | WO2023156979A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4580606A1 (en) * | 2022-08-31 | 2025-07-09 | Astrazeneca AB | Pharmaceutical formulation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| CA3048340A1 (en) | 2017-01-10 | 2018-07-19 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
| CN112867718B (zh) | 2018-09-29 | 2025-03-04 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物的制造 |
| IL305106B2 (en) | 2018-09-29 | 2025-08-01 | Novartis Ag | Process of manufacture of a compound for inhibiting the activity of shp2 |
| MX2021009562A (es) | 2019-02-12 | 2021-09-08 | Novartis Ag | Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1. |
| US20220152026A1 (en) | 2019-02-12 | 2022-05-19 | Novartis Ag | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor |
| EP3923941B1 (en) | 2019-02-12 | 2025-12-03 | Novartis AG | Pharmaceutical combination comprising tno155 and ribociclib |
| EP4110338A1 (en) | 2020-02-28 | 2023-01-04 | Novartis AG | A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor |
-
2023
- 2023-02-18 TW TW112105963A patent/TW202342040A/zh unknown
- 2023-02-20 US US18/839,600 patent/US20250161223A1/en active Pending
- 2023-02-20 KR KR1020247030717A patent/KR20240150600A/ko active Pending
- 2023-02-20 CN CN202380021982.XA patent/CN118715005A/zh active Pending
- 2023-02-20 JP JP2024548368A patent/JP2025508402A/ja active Pending
- 2023-02-20 WO PCT/IB2023/051532 patent/WO2023156979A1/en not_active Ceased
- 2023-02-20 AU AU2023221615A patent/AU2023221615A1/en active Pending
- 2023-02-20 IL IL314206A patent/IL314206A/en unknown
- 2023-02-20 CA CA3251234A patent/CA3251234A1/en active Pending
- 2023-02-20 MX MX2024009967A patent/MX2024009967A/es unknown
- 2023-02-20 EP EP23708903.2A patent/EP4482471A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL314206A (en) | 2024-09-01 |
| US20250161223A1 (en) | 2025-05-22 |
| JP2025508402A (ja) | 2025-03-26 |
| CA3251234A1 (en) | 2023-08-24 |
| WO2023156979A1 (en) | 2023-08-24 |
| CN118715005A (zh) | 2024-09-27 |
| KR20240150600A (ko) | 2024-10-15 |
| EP4482471A1 (en) | 2025-01-01 |
| MX2024009967A (es) | 2024-08-26 |
| TW202342040A (zh) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4066821B1 (en) | Tablet formulations of neratinib maleate | |
| US20220370448A1 (en) | Pharmaceutical composition comprising third generation small molecule egfr inhibitor and preparation method thereof | |
| US20130122093A1 (en) | Formulations of a src/abl inhibitor | |
| US20220249524A1 (en) | Pharmaceutical formulations comprising 5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine | |
| KR20190045286A (ko) | 로수바스타틴 및 에제티미브를 포함하는 제약 조성물 및 그의 제조 방법 | |
| US20250161223A1 (en) | Pharmaceutical formulation | |
| CN115708827A (zh) | 用于治疗异常细胞生长的组合物和方法 | |
| WO2006040779A2 (en) | Controlled release gastric floating matrix formulation containing imatinib | |
| CN114832112A (zh) | 含有alk激酶抑制剂的药物制剂组合物及其制备方法 | |
| KR102244108B1 (ko) | 티카그렐러 또는 이의 염을 함유하는 서방형 약제학적 조성물 | |
| US10709691B2 (en) | Pharmaceutical dosage forms | |
| KR101739731B1 (ko) | 유당불내성 환자에게 투여가 가능하며, 복용편의성이 향상된 게피티니브를 함유하는 약제학적 조성물 | |
| JP2020147542A (ja) | ダビガトランエテキシラートまたはその薬学的に許容される塩を含有する多層錠 | |
| CN119365195A (zh) | 含有匹米替比的医药组合物 | |
| WO2025252098A1 (zh) | Glp-1受体激动剂的口服药物组合物及其制备方法 | |
| HK40081563B (en) | Tablet formulations of neratinib maleate | |
| EA017781B1 (ru) | Покрытая пленочной оболочкой таблетка, содержащая иматиниб мезилат, и способ ее получения | |
| HK1260384A1 (en) | Pharmaceutical dosage forms | |
| EA041427B1 (ru) | Фармацевтические лекарственные формы | |
| WO2014128209A1 (en) | Pharmaceutical formulation comprising dpp-iv inhibitor agglomerates | |
| HK1231741A1 (en) | Pharmaceutical dosage forms | |
| HK1231741B (en) | Pharmaceutical dosage forms |